The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Pleural thickening - Fibrothorax
Publications
Acquired Platythorax, or Anteroposterior Flattening of the Chest Wall, as a Late Complication of Cyclophosphamide Treatment for Childhood Acute Lymphoblastic Leukemia, Presenting in a Young Man with Respiratory Failure.
The American journal of case reports 2018 Nov 05;19;1317-1323 — 2018 Nov 05 — 1317-1323
Pleuroparenchymal fibroelastosis in patients with pulmonary disease secondary to bone marrow transplantation.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2011 Dec;24;1633-9 — 2011 Dec — 1633-9
Cyclophosphamide-induced late-onset lung disease.
Internal medicine (Tokyo, Japan) 2003 Jan;42;82-7 — 2003 Jan — 82-7
Lung toxicity associated with cyclophosphamide use. Two distinct patterns.
American journal of respiratory and critical care medicine 1996 Dec;154;1851-6 — 1996 Dec — 1851-6
Lung transplantation for chemotherapy-induced pulmonary fibrosis.
Chest 1994 Jan;105;310-2 — 1994 Jan — 310-2
Progressive pulmonary fibrosis complicating cyclophosphamide therapy.
Acta medica Scandinavica 1987;221;403-7 — 1987 — 403-7